Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI)
Advances in Respiratory Medicine · 2024
DOI: 10.3390/arm92060049 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Advances in Respiratory Medicine, 2024. Verfasst von Tomke Sütering und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, 89075 Ulm, Germany. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Cystic Fibrosis Transmembrane Conductance Regulator, Indoles. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Elexacaftor/Tezacaftor/Ivacaftor (ETI) is a CFTR modulator therapy approved for people with cystic fibrosis (pwCF) who have at least one phe508del mutation. However, its approval in the European Union (EU) for pwCF with non-phe508del mutations is lacking, because data on treatment response in this subgroup are scarce.
Methods
This retrospective observational study evaluated six pwCF (ages 6 to 66) with responsive CFTR mutations (M1101K, R347P, 2789+5G>A, G551D) undergoing off-label ETI therapy. Evaluations were conducted at 0, 3, 6, 9, and 12 months, assessing lung function (FEV1), sweat chloride levels, body mass index (BMI), quality of life, medication satisfaction, ear, nose and throat (ENT) symptoms, and physical activity. A control group of four pwCF with classic symptoms and no ETI treatment was included.
Results
FEV1 improved significantly after 3 and 6 months (p < 0.05) and stabilized by 12 months. Sweat chloride levels decreased significantly, with four pwCF achieving levels
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, 89075 Ulm, Germany.
- Cystic Fibrosis Center Munich West, Ludwig Maximilian University (LMU), 81241 Munich, Germany.
ORCID-Profile: Sebastian F N Bode, Dorit Fabricius
Zitieren
APA
Sütering, T., Bode, S. F. N., Fischer, R., & Fabricius, D. (2024). Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI). Advances in Respiratory Medicine. https://doi.org/10.3390/arm92060049
Vancouver
Sütering T, Bode SFN, Fischer R, Fabricius D. Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI). Advances in Respiratory Medicine. 2024. doi:10.3390/arm92060049
BibTeX
@article{Stering2024,
author = {Sütering, Tomke and Bode, Sebastian F N and Fischer, Rainald and Fabricius, Dorit},
title = {Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI)},
journal = {Advances in Respiratory Medicine},
year = {2024},
doi = {10.3390/arm92060049}
}
EUVIMED